For this study, we launched the GLP-1 survey in the late summer of 2024, asking participants about their experiences with these medications, including drug brand, dosage, efficacy, and side effects
Key highlights Commercially available GLP-1 boosters or GLP-1 patches are not FDA-approved and do not contain GLP-1 molecules
Appetite suppression timelines vary from person to person, which is why proper dosing, monitoring, and metabolic support matter
Your provider will track your progress and adjust your treatment plan as needed to make sure you lose weight safely and effectively
The semaglutide segment has asserted its dominance in the market by securing a significant market share of 58.7% in 2025 stimulated by its broad commercial presence across multiple blockbuster brands, including Ozempic, Wegovy, and Rybelsus, as well as its established global manufacturing network and extensive patient adoption in diabetes and obesity management